Dermata Therapeutics, Inc.
DRMA
$3.01
$0.020.67%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.48M | 4.05M | 3.77M | 4.31M | 4.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.07M | 10.54M | 11.65M | 12.51M | 11.53M |
| Operating Income | -9.07M | -10.54M | -11.65M | -12.51M | -11.53M |
| Income Before Tax | -8.85M | -10.33M | -11.46M | -12.29M | -11.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.85 | -10.33 | -11.46 | -12.29 | -11.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.85M | -10.33M | -11.46M | -12.29M | -11.27M |
| EBIT | -9.07M | -10.54M | -11.65M | -12.51M | -11.53M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -17.95 | -36.72 | -75.87 | -141.99 | -199.59 |
| Normalized Basic EPS | -11.22 | -22.95 | -47.42 | -88.74 | -124.75 |
| EPS Diluted | -17.95 | -36.72 | -75.87 | -141.99 | -199.59 |
| Normalized Diluted EPS | -11.22 | -22.95 | -47.42 | -88.74 | -124.75 |
| Average Basic Shares Outstanding | 2.52M | 1.65M | 1.08M | 611.30K | 299.60K |
| Average Diluted Shares Outstanding | 2.52M | 1.65M | 1.08M | 611.30K | 299.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |